Clinical trial · Observational
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550CI-TRIAL-00025648unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Neutropenia, Febrile | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- CISL 14-03
- description
- * Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL). * Aged 19 or more * Treated with R-CHOP therapy
Primary outcomes (1)
- measure
- incidence of febrile neutropenia
- timeFrame
- within 30 days
Secondary outcomes (2)
- measure
- incidence of chemotherapy-related adverse events other than febrile neutropenia
- timeFrame
- 4 weeks after completion of chemotherapy
- measure
- Overall survival
- timeFrame
- 2 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * 19 or older * newly diagnosed with DLBCL * R-CHOP chemotherapy * offer informed consent Exclusion Criteria: * other subtype of NHL * concomitant other cancer * previous chemotherapy or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.